SCYNEXIS, Inc. (SCYX) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Win.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
27/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 8 wins, 4 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseSCYX / S&P -44.52% / 15.20% |
WinSCYX / S&P 489.78% / 15.00% |
LoseSCYX / S&P -121.17% / 50.40% |
| 2026-Q13/3 |
WinSCYX / S&P 45.09% / -4.33% |
WinSCYX / S&P 673.54% / 11.30% |
WinSCYX / S&P 158.93% / 27.70% |
| 2025-Q42/3 |
LoseSCYX / S&P -17.92% / 2.65% |
WinSCYX / S&P 449.95% / 9.00% |
WinSCYX / S&P 159.09% / 13.40% |
| 2025-Q32/3 |
WinSCYX / S&P 14.07% / 8.12% |
LoseSCYX / S&P -65.77% / 4.61% |
WinSCYX / S&P 100.00% / 13.45% |
| 2025-Q21/3 |
LoseSCYX / S&P -29.10% / 10.94% |
LoseSCYX / S&P -66.30% / 4.83% |
WinSCYX / S&P 90.28% / 10.63% |
| 2025-Q10/3 |
LoseSCYX / S&P -21.32% / -4.27% |
LoseSCYX / S&P -98.13% / 4.98% |
LoseSCYX / S&P -127.45% / 10.57% |
| 2024-Q40/3 |
LoseSCYX / S&P -18.79% / 2.41% |
LoseSCYX / S&P -97.33% / 5.25% |
LoseSCYX / S&P -133.33% / 6.15% |
| 2024-Q30/3 |
LoseSCYX / S&P -25.50% / 5.89% |
LoseSCYX / S&P -93.70% / 5.89% |
LoseSCYX / S&P -152.11% / 6.11% |
| 2024-Q21/3 |
WinSCYX / S&P 36.05% / 4.28% |
LoseSCYX / S&P -92.87% / 5.38% |
LoseSCYX / S&P -185.71% / 5.12% |
| 2024-Q11/3 |
LoseSCYX / S&P -34.08% / 10.56% |
WinSCYX / S&P 2436.77% / 5.71% |
LoseSCYX / S&P -205.70% / 5.59% |
| 2023-Q41/3 |
LoseSCYX / S&P -2.19% / 11.69% |
WinSCYX / S&P 2652.74% / 6.81% |
LoseSCYX / S&P -194.29% / 7.78% |
| 2023-Q31/3 |
LoseSCYX / S&P -22.71% / -3.27% |
WinSCYX / S&P 3162.94% / 7.52% |
LoseSCYX / S&P -187.12% / -5.03% |
| 2023-Q21/3 |
LoseSCYX / S&P -1.67% / 8.74% |
WinSCYX / S&P 4244.06% / 9.50% |
LoseSCYX / S&P -178.50% / -8.57% |
| 2023-Q13/3 |
WinSCYX / S&P 92.31% / 7.50% |
WinSCYX / S&P 207.44% / 10.77% |
WinSCYX / S&P 96.94% / -15.69% |
| 2022-Q41/3 |
LoseSCYX / S&P -35.00% / 7.56% |
LoseSCYX / S&P -61.32% / 11.88% |
WinSCYX / S&P 35.92% / -17.99% |
| 2022-Q31/3 |
WinSCYX / S&P 29.03% / -4.88% |
LoseSCYX / S&P -66.86% / 13.47% |
LoseSCYX / S&P SCYX unavailable / -1.41% |
| 2022-Q20/3 |
LoseSCYX / S&P -52.43% / -16.10% |
LoseSCYX / S&P -74.08% / 13.71% |
LoseSCYX / S&P SCYX unavailable / 11.04% |
| 2022-Q10/3 |
LoseSCYX / S&P -35.90% / -4.60% |
LoseSCYX / S&P -85.06% / 15.97% |
LoseSCYX / S&P SCYX unavailable / 42.23% |
| 2021-Q41/3 |
WinSCYX / S&P 15.09% / 11.03% |
LoseSCYX / S&P SCYX unavailable / 15.00% |
LoseSCYX / S&P SCYX unavailable / 96.40% |
| 2021-Q30/3 |
LoseSCYX / S&P -27.99% / 0.58% |
LoseSCYX / S&P SCYX unavailable / 10.77% |
LoseSCYX / S&P SCYX unavailable / 69.42% |
| 2021-Q20/3 |
LoseSCYX / S&P -7.30% / 8.55% |
LoseSCYX / S&P SCYX unavailable / 6.58% |
LoseSCYX / S&P SCYX unavailable / 51.81% |
| 2021-Q11/3 |
LoseSCYX / S&P 3.79% / 6.17% |
WinSCYX / S&P 21040.35% / -1.06% |
LoseSCYX / S&P SCYX unavailable / 7.39% |
| 2020-Q41/3 |
WinSCYX / S&P 73.47% / 12.15% |
LoseSCYX / S&P -100.00% / -3.72% |
LoseSCYX / S&P SCYX unavailable / -33.42% |
| 2020-Q30/3 |
LoseSCYX / S&P -41.28% / 8.93% |
LoseSCYX / S&P -100.00% / -2.04% |
LoseSCYX / S&P SCYX unavailable / -27.10% |
| 2020-Q20/3 |
LoseSCYX / S&P -3.84% / 20.54% |
LoseSCYX / S&P -100.00% / -0.46% |
LoseSCYX / S&P SCYX unavailable / -27.11% |
| 2020-Q11/3 |
WinSCYX / S&P -14.18% / -19.60% |
LoseSCYX / S&P -77.73% / 3.47% |
LoseSCYX / S&P SCYX unavailable / -14.75% |
| 2019-Q40/3 |
LoseSCYX / S&P -14.55% / 9.07% |
LoseSCYX / S&P -52.73% / 5.36% |
LoseSCYX / S&P SCYX unavailable / 2.99% |
| 2019-Q30/3 |
LoseSCYX / S&P -18.70% / 1.70% |
LoseSCYX / S&P -27.73% / 5.02% |
LoseSCYX / S&P SCYX unavailable / 0.21% |
| 2019-Q20/3 |
LoseSCYX / S&P -13.25% / 4.30% |
LoseSCYX / S&P -2.73% / 6.64% |
LoseSCYX / S&P SCYX unavailable / 8.65% |
| 2019-Q11/3 |
WinSCYX / S&P 213.28% / 13.65% |
LoseSCYX / S&P 0.00% / 8.12% |
LoseSCYX / S&P SCYX unavailable / 14.29% |
| 2018-Q40/3 |
LoseSCYX / S&P -59.83% / -13.52% |
LoseSCYX / S&P 0.00% / 9.05% |
LoseSCYX / S&P SCYX unavailable / 18.23% |
| 2018-Q30/3 |
LoseSCYX / S&P -26.83% / 7.71% |
LoseSCYX / S&P 0.00% / 10.21% |
LoseSCYX / S&P SCYX unavailable / 19.06% |
| 2018-Q21/3 |
WinSCYX / S&P 22.39% / 3.43% |
LoseSCYX / S&P 0.00% / 9.03% |
LoseSCYX / S&P SCYX unavailable / 14.46% |
| 2018-Q10/3 |
LoseSCYX / S&P -42.24% / -0.76% |
LoseSCYX / S&P 0.00% / 7.68% |
LoseSCYX / S&P SCYX unavailable / 12.46% |
| 2017-Q40/3 |
LoseSCYX / S&P -3.73% / 6.64% |
LoseSCYX / S&P 0.00% / 7.03% |
LoseSCYX / S&P SCYX unavailable / 13.82% |
| 2017-Q31/3 |
WinSCYX / S&P 34.64% / 4.48% |
LoseSCYX / S&P 0.00% / 5.68% |
LoseSCYX / S&P SCYX unavailable / 17.57% |
| 2017-Q20/3 |
LoseSCYX / S&P -35.14% / 3.09% |
LoseSCYX / S&P 0.00% / 4.83% |
LoseSCYX / S&P SCYX unavailable / 17.74% |
| 2017-Q10/3 |
LoseSCYX / S&P -13.48% / 6.07% |
LoseSCYX / S&P 0.00% / 3.67% |
LoseSCYX / S&P SCYX unavailable / 13.32% |
| 2016-Q40/3 |
LoseSCYX / S&P -17.57% / 3.82% |
LoseSCYX / S&P -89.77% / 2.09% |
LoseSCYX / S&P SCYX unavailable / 7.05% |
| 2016-Q31/3 |
WinSCYX / S&P 78.34% / 3.85% |
LoseSCYX / S&P -95.67% / 0.20% |
LoseSCYX / S&P SCYX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | SCYX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -16.97% | 20.78% |
| Annualized return | -16.97% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | SCYX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -89.15% | 83.14% |
| Annualized return | -35.87% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | SCYX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -97.60% | 319.30% |
| Annualized return | -31.12% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |